Kytron Special Precautions

As Kytron Solution for Injection/Infusion 3 mg/3 ml may reduce lower bowel motility, patients with signs of sub-acute intestinal obstruction should be monitored following administration of Kytron Solution for Injection/Infusion 3 mg/3 ml. Therefore, caution should be exercised in patients with cardiac co-morbidities, on cardio-toxic chemotherapy and/or with concomitant electrolyte abnormalities. There are no data on the effect on Kytron Solution for Injection/Infusion 3 mg/3 ml on the ability to drive, however there have been occasional reports of somnolence in clinical studies which should be taken in to account. No special precautions are required for the elderly or patients with renal or hepatic impairment. Cross-sensitivity between 5-HT3 antagonists has been reported. As with other 5-HT3 antagonists, cases of serotonin syndrome (including altered mental status, autonomic dysfunction and neuromuscular abnormalities) have been reported following the concomitant use of Kytron Solution for Injection/Infusion 3 mg/3 ml and other serotonergic drugs. If concomitant treatment with granisetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised. As for other 5-HT3 anatagonists, cases of ECG modifications including QT prolongation have been reported with Kytron Solution for Injection/Infusion 3 mg/3 ml. The ECG changes with Kytron Solution for Injection/Infusion 3 mg/3 ml were minor, generally not of clinical significance and specifically, there was no evidence of proarrhythmia. However, in patients concurrently treated with drugs, known to prolong QT interval and/or are arrhythmogenic, this may lead to clinical consequences.